However, our data predict that targeting the α2M*/CS-GRP78 signaling provides a potential advantage over cancer with metabolic reprogramming because CS-GRP78 is a potent activator of PI 3-kinase/AKT pathway which regulates both glucose and lipid metabolism [33, 36, 54] as well as ACLY and ACSS1 expression levels and their activity. Here, ACLY is linked to cancer.